• Simulations Plus launched technical collaboration with NVIDIA to scale GPU-accelerated simulation and AI-assisted modeling workflows across drug development.
• Partnership aims to speed simulation cycles, parameter exploration, virtual population studies by combining Simulations Plus PBPK, PK/PD, QSP engines with NVIDIA accelerated computing, inference, GPU-native optimization.
• Initial work targets GPU-optimized QSP, PK/PD simulation engines plus AI-assisted model construction, parameter fitting, diagnostics to cut manual effort.
• Testing to date showed up to 75% reduction in end-to-end QSP modeling time.
• Companies plan to engage select pharmaceutical partners to evaluate workflows in real-world, high-complexity modeling use cases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Simulations Plus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260506350085) on May 06, 2026, and is solely responsible for the information contained therein.